Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Retained Earnings (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Retained Earnings data on record, last reported at -$505000.0 in Q1 2026.

  • On a quarterly basis, Retained Earnings rose 99.66% to -$505000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$505000.0, a 99.66% increase, with the full-year FY2025 number at -$235.2 million, down 44962.84% from a year prior.
  • Retained Earnings reached -$505000.0 in Q1 2026 per RAPP's latest filing, up from -$235.2 million in the prior quarter.
  • Over the last five years, Retained Earnings for RAPP hit a ceiling of $400000.0 in Q3 2024 and a floor of -$235.2 million in Q4 2025.
  • A 4-year average of -$84.4 million and a median of -$522000.0 in 2024 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 95277.05% in 2025, then soared 99.66% in 2026.
  • Tracing RAPP's Retained Earnings over 4 years: stood at $4000.0 in 2023, then crashed by 13150.0% to -$522000.0 in 2024, then crashed by 44962.84% to -$235.2 million in 2025, then surged by 99.79% to -$505000.0 in 2026.
  • Business Quant data shows Retained Earnings for RAPP at -$505000.0 in Q1 2026, -$235.2 million in Q4 2025, and -$201.5 million in Q3 2025.